title: Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial.
abstract: BACKGROUND
  Controversy exists regarding the frequency of late stent thrombosis among patients treated with intracoronary stents and the most appropriate duration of treatment with a thienopyridine that is required to prevent this complication.
  
  
  METHODS
  We analyzed the frequency of stent thrombosis and other ischemic events in the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. In the ATLAST trial, 1102 patients at increased risk of stent thrombosis (ST-elevation myocardial infarction within 48 hours, diffuse distal disease, a large amount of thrombus, acute closure, residual dissection, etc) were randomly assigned to receive either enoxaparin (40 or 60 mg given every 12 hours for 14 days) or placebo; all patients received aspirin (325 mg daily) and ticlopidine (250 mg twice daily) for only 14 days.
  
  
  RESULTS
  The primary end point, the 30-day combined incidence of death, nonfatal myocardial infarction, and urgent revascularization, was reached in 2.3% of patients (1.8% of patients taking enoxaparin vs 2.7% of patients taking placebo; P =.295). However, during the 15th through 30th days, the frequency of ischemic events was only 0.73%, and only 0.27% (3/1102) of patients had possible stent thrombosis (95% CI 0.06, 0.77).
  
  
  CONCLUSIONS
  The frequency of stent thrombosis and other adverse ischemic events in the 15th through 30th days after stent placement in even high-risk stent patients treated with ticlopidine for only 2 weeks is low whether or not enoxaparin is administered.
authors.affiliation: Mayo Clinic, Rochester, MN 55905, USA. berger.peter@mayo.edu
authors.forename: Peter B
authors.initials: PB
authors.lastname: Berger
authors.forename: Ken W
authors.initials: KW
authors.lastname: Mahaffey
authors.forename: Susan J
authors.initials: SJ
authors.lastname: Meier
authors.forename: Christopher E
authors.initials: CE
authors.lastname: Buller
authors.forename: Wayne
authors.initials: W
authors.lastname: Batchelor
authors.forename: Edward T A
authors.initials: ET
authors.lastname: Fry
authors.forename: James P
authors.initials: JP
authors.lastname: Zidar
mesh_terms: D003328:Coronary Thrombosis / Q000209:etiology / Q000517:prevention & control* / Q000628:therapy; D017984:Enoxaparin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D015607:Stents / Q000009:adverse effects*; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors
chemical_list: D017984:Enoxaparin; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine